Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Medicinal Research Reviews|May 24, 2021
The antigen-binding moiety in the driver's seat of CARsHeleen Hanssens, Fien Meeus, Kim De Veirman, et al.
Pharmaceuticals (Basel, Switzerland)|April 30, 2021
Decorating sdAbs with Chelators: Effect of Conjugation on Biodistribution and FunctionalityHenri Baudhuin, Janik Puttemans, Heleen Hanssens, et al.
Theranostics|November 8, 2019
Theranostics in immuno-oncology using nanobody derivativesQuentin Lecocq, Yannick De Vlaeminck, Heleen Hanssens, et al.
International Journal of Molecular Sciences|June 19, 2024
Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding MoietiesHeleen Hanssens, Fien Meeus, Emma L Gesquiere, et al.
Frontiers in Immunology|May 9, 2024
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimizationHeleen Hanssens, Fien Meeus, Yannick De Vlaeminck, et al.
Oncoimmunology|November 15, 2021
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple MyelomaKim De Veirman, Janik Puttemans, Ahmet Krasniqi, et al.
Cancers|April 25, 2020
Preclinical Targeted α- and β<sup>-</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain AntibodiesJanik Puttemans, Yana Dekempeneer, Jos L Eersels, et al.
Molecular Cancer Therapeutics|October 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide TherapyJanik Puttemans, Benoit Stijlemans, Marleen Keyaerts, et al.
International Review of Cell and Molecular Biology|July 1, 2022
Emerging applications of nanobodies in cancer therapyRobin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, et al.
Journal of Hematology & Oncology|November 14, 2025
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escapeArne Van der Vreken, Fien Meeus, Chenggong Tu, et al.
Pageof 1